About: Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies
Creator	Braz-Gomes, Kim Chiriva-Internati, Maurizio Zughaier, Susu D'sa, Sucheta D'souza, Bernadette D'souza, Marissa D'souza, Martin D'souza, Nigel Gala, Rikhav Mulla, Nihal Parenky, Ashwin Ubale, Ruhi Vo, Trinh
source	Elsevier; PMC
abstract	Abstract Recent years have witnessed the development and advancement of many nonparenteral biologics and vaccines for human use. This chapter discusses various nonparenteral routes of administration. The oral route of administration is the most preferred and patient compliant method of them all. Transdermal, buccal, and pulmonary routes are also discussed. We have developed novel technologies using nanoparticles and microparticles to deliver vaccines by the oral and transdermal route of administration. These new technologies enable the formulation of vaccine particles containing vaccine antigens, without loss of their biological activity during the formulation process. Also, multiple antigens, targeting ligands and adjuvants can all be encapsulated within the same particle. When administered orally, these particles are designed to withstand the acidic environment of the stomach and are targeted to the Peyer’s patches and the gut-associated mucosal immune system. Because these vaccines are particulate in nature, they are readily taken up by phagocytic antigen presenting cells (APCs), such as M cells, dendritic cells, and macrophages in the Peyer’s patches of the intestines, resulting in a strong immune response and antibody production. Of particular interest is the fact that the particles release the antigen in a slow and sustained manner over a prolonged time period, intracellularly into APCs, resulting in strong mucosal and systemic immunity after oral administration, without the need for added adjuvants that are typically present in current vaccine preparations. Because no needles are required for oral vaccines, this method of vaccine delivery is inexpensive and suitable for mass vaccination in the developing world as well as for the developed world. This chapter discusses studies conducted on a wide array of vaccines, including infectious disease vaccines and cancer vaccines. This method of vaccine delivery enables the delivery of a wide spectrum of vaccines for prophylactic and therapeutic use, including oral and transdermal vaccines for cancer such as human papillomavirus, melanoma, ovarian, breast, and prostate with encouraging results. With respect to cancer therapy, a comparison is made between the conventional cancer therapy and immunotherapy. With a wide range of nanocarriers available for delivery of biologics, vaccines, and cancer therapies, nanotechnology not only has gained the well-deserved limelight but has also attracted the attention of regulatory bodies, although it presents certain challenges that must be considered before marketing such nanocarriers.
has issue date	2015-12-31(xsd:dateTime)
bibo:doi	10.1016/b978-0-12-416603-5.00005-5
has license	els-covid
sha1sum (hex)	6f6c1cccdaf6a2a22ffdd30f2eeadba5f063c30f
schema:url	https://doi.org/10.1016/b978-0-12-416603-5.00005-5
resource representing a document's title	Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies
has PubMed Central identifier	PMC7150203
schema:publication	Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies
resource representing a document's body	covid:6f6c1cccdaf6a2a22ffdd30f2eeadba5f063c30f#body_text
is schema:about of	named entity 'Vaccines' named entity 'CANCER THERAPIES' named entity 'TRENDS' named entity 'NOVEL' named entity 'APPROACHES' named entity 'STRATEGIES' named entity 'BIOLOGICS' named entity 'DELIVERY' named entity 'VACCINES' named entity 'Vaccines' named entity 'Biologics' named entity 'Vaccines' named entity 'Cancer Therapies' named entity 'Cancer Therapies' named entity 'Novel' named entity 'Biologics' named entity 'Cancer' named entity 'Strategies' named entity 'Cancer' named entity 'Biologics' named entity 'Vaccines'
is part of of	Abstract Recent years have witnessed the development and advancement of many nonparenteral biologics and vaccines for human use. This chapter discusses various nonparenteral routes of administration. The oral route of administration is the most preferred and patient compliant method of them all. Transdermal, buccal, and pulmonary routes are also discussed. We have developed novel technologies using nanoparticles and microparticles to deliver vaccines by the oral and transdermal route of administration. These new technologies enable the formulation of vaccine particles containing vaccine antigens, without loss of their biological activity during the formulation process. Also, multiple antigens, targeting ligands and adjuvants can all be encapsulated within the same particle. When administered orally, these particles are designed to withstand the acidic environment of the stomach and are targeted to the Peyer’s patches and the gut-associated mucosal immune system. Because these vaccines are particulate in nature, they are readily taken up by phagocytic antigen presenting cells (APCs), such as M cells, dendritic cells, and macrophages in the Peyer’s patches of the intestines, resulting in a strong immune response and antibody production. Of particular interest is the fact that the particles release the antigen in a slow and sustained manner over a prolonged time period, intracellularly into APCs, resulting in strong mucosal and systemic immunity after oral administration, without the need for added adjuvants that are typically present in current vaccine preparations. Because no needles are required for oral vaccines, this method of vaccine delivery is inexpensive and suitable for mass vaccination in the developing world as well as for the developed world. This chapter discusses studies conducted on a wide array of vaccines, including infectious disease vaccines and cancer vaccines. This method of vaccine delivery enables the delivery of a wide spectrum of vaccines for prophylactic and therapeutic use, including oral and transdermal vaccines for cancer such as human papillomavirus, melanoma, ovarian, breast, and prostate with encouraging results. With respect to cancer therapy, a comparison is made between the conventional cancer therapy and immunotherapy. With a wide range of nanocarriers available for delivery of biologics, vaccines, and cancer therapies, nanotechnology not only has gained the well-deserved limelight but has also attracted the attention of regulatory bodies, although it presents certain challenges that must be considered before marketing such nanocarriers. Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies covid:6f6c1cccdaf6a2a22ffdd30f2eeadba5f063c30f#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software